Kdr - kinase insert domain protein receptor Gene

中文名称：激酶插入域蛋白受体

种属: Mus musculus

同用名: orv; Flk1; Ly73; Flk-1; Krd-1; VEGFR2; VEGFR-2; sVEGFR-2; 6130401C07

基因 ID: 16542 | 基因类型: protein coding

关于 Kdr

Chromosome 5: 76,093,487-76,139,118 reverse strand.GRCm39:CM000998.3

This gene has 3 transcripts (splice variants), 199 orthologues, 53 paralogues and is associated with 30 phenotypes. Broad expression in lung adult (RPKM 42.4), heart adult (RPKM 19.3) and 22 other tissues.

功能概要

该基因编码的蛋白可启动生长因子结合活性和血管内皮生长因子激活受体活性。参与多个过程，包括循环系统发育；肽基酪氨酸自磷酸化；和血管生成的正调节。作用于多个过程的上游或内部，包括动物器官发育；细胞群增殖的正向调节；和血管发育。位于多个细胞成分中，包括细胞连接；核内体；和质膜的外侧。以多种结构表达，包括消化系统；心血管系统;中枢神经系统;胚外成分；和泌尿生殖系统。该基因的人类直系同源物与多种疾病有关，包括子宫粘连；动脉疾病（多发性）；胃肠系统癌症（多发性）；黄斑变性（多发性）；和胰腺癌（多发）。与人类 KDR（激酶插入域受体）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables growth factor binding activity and vascular endothelial growth factor-activated receptor activity. Involved in several processes, including circulatory system development; peptidyl-tyrosine autophosphorylation; and positive regulation of vasculogenesis. Acts upstream of or within several processes, including animal organ development; positive regulation of cell population proliferation; and vasculature development. Located in several cellular components, including cell junction; endosome; and external side of plasma membrane. Is expressed in several structures, including alimentary system; cardiovascular system; central nervous system; extraembryonic component; and genitourinary system. Human ortholog(s) of this gene implicated in several diseases, including adhesions of uterus; artery disease (multiple); gastrointestinal system Cancer (multiple); macular degeneration (multiple); and pancreatic Cancer (multiple). Orthologous to human VEGFR2/KDR/Flk-1 (kinase insert domain receptor). [provided by Alliance of Genome Resources, Apr 2022]

Kdr 基因产物(6)

mRNA	Protein	Name
NM_001403141.1	NP_001390070.1	vascular endothelial growth factor receptor 2 isoform 1 precursor
NM_001403144.1	NP_001390073.1	vascular endothelial growth factor receptor 2 isoform 5
NM_001363216.1	NP_001350145.1	vascular endothelial growth factor receptor 2 isoform 2 precursor
NM_001403143.1	NP_001390072.1	vascular endothelial growth factor receptor 2 isoform 4 precursor
NM_001403142.1	NP_001390071.1	vascular endothelial growth factor receptor 2 isoform 3 precursor
NM_010612.3	NP_034742.2	vascular endothelial growth factor receptor 2 isoform 1 precursor

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables coreceptor activity	IGI IGI: 通过遗传相互作用推断	25985275	MGI
enables growth factor binding	IPI IPI: 通过物理相互作用推断	7681362	MGI
enables protein binding	IPI IPI: 通过物理相互作用推断	14977921	MGI
enables vascular endothelial growth factor receptor activity	IDA IDA: 通过直接分析推断	8356051	MGI

生物过程 GO 注释	逻辑证据	参考文献	来源
acts upstream of or within blood vessel endothelial cell differentiation	IMP IMP: 通过突变表型推断	15644447	MGI
acts upstream of or within branching morphogenesis of an epithelial tube	IMP IMP: 通过突变表型推断	16375885	MGI
acts upstream of or within calcium ion homeostasis	IDA IDA: 通过直接分析推断	8356051	MGI
acts upstream of or within cell fate commitment	IMP IMP: 通过突变表型推断	12569129	MGI
acts upstream of or within cell migration	IGI IGI: 通过遗传相互作用推断	15601856	MGI
involved in cell migration involved in sprouting angiogenesis	IMP IMP: 通过突变表型推断	20660291	MGI
involved in embryonic hemopoiesis	IMP IMP: 通过突变表型推断	7596435	MGI
involved in endocardium development	IMP IMP: 通过突变表型推断	7596435	MGI
acts upstream of or within endothelial cell differentiation	IDA IDA: 通过直接分析推断	12897140	MGI
acts upstream of or within endothelial cell differentiation	IMP IMP: 通过突变表型推断	18772315	MGI
involved in endothelium development	IMP IMP: 通过突变表型推断	7596435	MGI
acts upstream of or within epithelial cell maturation	IMP IMP: 通过突变表型推断	12053176	MGI
acts upstream of epithelial cell proliferation	IMP IMP: 通过突变表型推断	16375885	MGI
acts upstream of or within hemopoiesis	IMP IMP: 通过突变表型推断	15644447	MGI
acts upstream of or within lung alveolus development	IMP IMP: 通过突变表型推断	12053176	MGI
acts upstream of or within lung development	IMP IMP: 通过突变表型推断	16375885	MGI
acts upstream of or within lymph vessel development	IGI IGI: 通过遗传相互作用推断	20439428	MGI
acts upstream of mesenchymal cell proliferation	IMP IMP: 通过突变表型推断	16375885	MGI
involved in negative regulation of neuron apoptotic process	IGI IGI: 通过遗传相互作用推断	25985275	MGI
acts upstream of or within ovarian follicle development	IMP IMP: 通过突变表型推断	17050862	MGI
involved in peptidyl-tyrosine autophosphorylation	IDA IDA: 通过直接分析推断	20660291	MGI
involved in positive regulation of BMP signaling pathway	IDA IDA: 通过直接分析推断	20406889	MGI
involved in positive regulation of angiogenesis	IDA IDA: 通过直接分析推断	20406889	MGI
acts upstream of or within positive regulation of epithelial cell proliferation	IMP IMP: 通过突变表型推断	16375885	MGI
acts upstream of or within positive regulation of mesenchymal cell proliferation	IMP IMP: 通过突变表型推断	16375885	MGI
acts upstream of or within positive regulation of stem cell proliferation	IMP IMP: 通过突变表型推断	16375885	MGI
involved in positive regulation of vasculogenesis	IMP IMP: 通过突变表型推断	19635461	MGI
acts upstream of or within post-embryonic camera-type eye morphogenesis	IGI IGI: 通过遗传相互作用推断	22426483	MGI
acts upstream of or within regulation of bone development	IMP IMP: 通过突变表型推断	22886301	MGI
acts upstream of or within regulation of hematopoietic progenitor cell differentiation	IMP IMP: 通过突变表型推断	18772315	MGI
involved in semaphorin-plexin signaling pathway	IGI IGI: 通过遗传相互作用推断	25985275	MGI
acts upstream of stem cell proliferation	IMP IMP: 通过突变表型推断	16375885	MGI
acts upstream of or within surfactant homeostasis	IMP IMP: 通过突变表型推断	12053176	MGI
acts upstream of or within vascular endothelial growth factor receptor signaling pathway	IDA IDA: 通过直接分析推断	8356051	MGI
acts upstream of or within vasculogenesis	IMP IMP: 通过突变表型推断	15644447	MGI
involved in vasculogenesis	IMP IMP: 通过突变表型推断	7596435	MGI

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in cell junction	IDA IDA: 通过直接分析推断	19635461	MGI
located in cell periphery	IDA IDA: 通过直接分析推断	16099728	MGI
located in cell surface	IDA IDA: 通过直接分析推断	22265737	MGI
located in cytoplasm	IDA IDA: 通过直接分析推断	22886301	MGI
located in early endosome	IDA IDA: 通过直接分析推断	20660291	MGI
located in external side of plasma membrane	IDA IDA: 通过直接分析推断	16455951	MGI
located in nucleus	IDA IDA: 通过直接分析推断	22886301	MGI
located in plasma membrane	IDA IDA: 通过直接分析推断	20660291	MGI
located in sorting endosome	IDA IDA: 通过直接分析推断	23639442	MGI

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

Kdr 蛋白结构

Ig_3

I-set

VEGFR-2_TMD

PTKc_VEGFR2

0
300
600
900
1200
1345 a.a.

蛋白主名

其他名称

vascular endothelial growth factor receptor 2

VEGF receptor-2	fetal liver kinase 1
kinase NYK	protein-tyrosine kinase receptor flk-1
soluble vascular endothelial growth factor receptor 2	vascular endothelial growth factor receptor-3

重组 Kdr 蛋白

目录号	产品名	蛋白编号	纯度
HY-P72429	VEGFR-2 Protein, Mouse (743a.a, HEK293, Fc)	P35918 (A20-E762)	≥95%
HY-P74471	VEGFR-2 Protein, Mouse (HEK293, His)	P35918 (M1-E762)	≥95%
HY-P74472	VEGFR-2 Protein, Mouse (Biotinylated, HEK293, His)	P35918 (M1-E762)	≥95%

相关产品

Approval

生物活性分子 (9)

目录号	产品名	作用方式	纯度	是否罕见病
HY-16749	Pexidartinib		99.64%	是
HY-10260	Vandetanib		99.95%	是
HY-112306	Ripretinib		98.90%	是
HY-16749A	Pexidartinib hydrochloride		99.86%	是
HY-14914	Azilsartan		99.51%	否
HY-10330	Toceranib	Inhibitor	96.86%	否
HY-10330A	Toceranib phosphate	Inhibitor	98.54%	否
HY-10260B	Vandetanib hydrochloride		/	否
HY-10260A	Vandetanib trifluoroacetate		/	否

Clinical Phase

生物活性分子 (16)

目录号	产品名	作用方式	纯度	Phase
HY-50751	Linifanib		99.28%	Phase 3
HY-10205	Cediranib		99.58%	Phase 3
HY-13314	Tesevatinib	Inhibitor	99.21%	Phase 3
HY-12018	Vatalanib dihydrochloride		99.91%	Phase 3
HY-13049	Cediranib maleate		99.95%	Phase 3
HY-10203	Vatalanib	Inhibitor	99.93%	Phase 3
HY-12018A	Vatalanib hydrochloride	Inhibitor	/	Phase 3
HY-50751G	Linifanib (GMP)	Inhibitor	/	Phase 3
HY-110272	Vatalanib succinate	Inhibitor	/	Phase 3
HY-10374	Semaxinib	Inhibitor	99.96%	Phase 2
HY-13024	Rebastinib		99.91%	Phase 2
HY-10338	Foretinib	Inhibitor	99.06%	Phase 2
HY-10987A	ENMD-2076		99.12%	Phase 2
HY-10987	ENMD-2076 Tartrate		99.42%	Phase 2
HY-10204	OSI-930		98.57%	Phase 1
HY-100315	XL 999	Inhibitor	99.34%	Phase 1

抗体抑制剂 (2)

目录号	产品名	作用方式	纯度	Phase
HY-P99830	Conbercept		98.42%	Phase 4
HY-P99768	Olinvacimab	Inhibitor	95.00%	Phase 2

Pre-clinical Phase

生物活性分子 (37)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-12299	WH-4-023	Inhibitor	99.75%	否
HY-151361	AMPK-IN-3	Inhibitor	98.51%	否
HY-W062835	CGP77675	Inhibitor	99.00%	否
HY-13561	AZM475271	Inhibitor	99.85%	否
HY-13838	PLX647	Inhibitor	99.79%	否
HY-133551	WF-47-JS03	Inhibitor	99.63%	否
HY-101219	VEGFR-IN-1	Inhibitor	98.42%	否
HY-132135	(1E)-CFI-400437 dihydrochloride	Inhibitor	98.08%	否
HY-18302	c-Kit-IN-5-1	Inhibitor	98.16%	否
HY-15769	WHI-P180	Inhibitor	99.62%	否
HY-125741	GW768505A free base	Inhibitor	98.66%	否
HY-10517A	(Z)-Orantinib	Inhibitor	99.44%	否
HY-13785	ZM 306416	Inhibitor	99.80%	否
HY-119757	Tyrphostin AG1433	Inhibitor	99.08%	否
HY-15814	HG-7-85-01		99.94%	否
HY-100824	PP2 Analog	Inhibitor	/	否
HY-10260S	Vandetanib-d6		/	否
HY-10260S1	Vandetanib-d4		/	否
HY-10260S2	Vandetanib-13C6		/	否
HY-120214	TAS05567	Inhibitor	/	否
HY-13838A	PLX647 dihydrochloride	Inhibitor	/	否
HY-14979	ML786	Inhibitor	/	否
HY-14979A	ML786 dihydrochloride	Inhibitor	/	否
HY-15334	CEP-5214	Inhibitor	/	否
HY-168114	Multi-kinase inhibitor 3	Inhibitor	/	否
HY-168115	Multi-kinase inhibitor 4	Inhibitor	/	否
HY-18318	Takeda-6D	Inhibitor	/	否
HY-RS07226	KDR Human Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-RS07227	Kdr Mouse Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-RS07228	Kdr Rat Pre-designed siRNA Set A	Pre-designed Sets	/	否
HY-W062835A	CGP77675 hydrate	Inhibitor	/	否
HY-10330S	Toceranib-d8	Inhibitor	/	否
HY-110045	ZM-306416 hydrochloride	Inhibitor	/	否
HY-119757A	Tyrphostin AG1433 hydrochloride	Inhibitor	/	否
HY-149451	SYHA1815	Inhibitor	/	否
HY-15769A	WHI-P180 hydrochloride	Inhibitor	/	否
HY-101628	VEGFR-2-IN-9	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Kdr	NCBI	NCBI:3791
Macaca fascicularis	Kdr	NCBI	NCBI:102136227
Rattus norvegicus	Kdr	NCBI	NCBI:25589
Macaca mulatta	Kdr	NCBI	NCBI:698293

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4